Key Highlights

  • LQDA reported second-quarter 2026 Revenue of $171.7 million, beating the $168.5 million estimate by 1.90 percent, with adjusted EPS of $0.74 topping the $0.70 estimate by 5.71 percent.
  • YUTREPIA net product sales reached $170.4 million, up 31 percent quarter over quarter, with more than 5,000 patients started on therapy and over 1,100 prescribing physicians as of July 31.
  • Net income rose to approximately $74.7 million and adjusted EBITDA increased to approximately $96.3 million, with the company ending the quarter with $284.2 million in cash.
  • Management reiterated confidence in exceeding $1 billion in net revenue in 2027, citing linear growth in patient referrals and new starts since launch.

YUTREPIA Growth Outpaces the Broader Inhaled Prostacyclin Market

Liquidia Corporation (NASDAQ:LQDA) reported that the overall inhaled prostacyclin market grew approximately 6 percent sequentially to $607 million in the quarter, while YUTREPIA's own growth alone exceeded the expansion of the entire category, even as management said usage of oral and other inhaled formulations was flat to declining. On a net revenue basis, YUTREPIA now represents approximately 30 percent of the entire inhaled prostacyclin market roughly one year into its commercial launch.

Management attributed the growth to the product's tolerability profile, which it said allows for higher dosing and correspondingly greater efficacy without a proportional increase in adverse events, a dynamic the company believes explains both new patient starts and switches from competing therapies. Because the inhaled prostacyclin category itself is still expanding alongside YUTREPIA's share gains, sustaining this dual growth dynamic will depend on continued category expansion as much as continued competitive share gains.

R&D Investment to Accelerate as Pipeline Studies Ramp

The company said Research and Development expense is expected to double in the second half of 2026 relative to the first half, and increase again in 2027, as enrollment ramps in the Phase III RESPIRE trial for its twice-daily L606 formulation and as the company initiates additional studies evaluating YUTREPIA in new patient populations, including a planned 2027 study in interstitial lung disease subtypes. Management said this investment is being made possible by the Cash Flow YUTREPIA now generates, and cash and cash equivalents grew to $284.2 million during the quarter even as spending increased.

With 10 clinical studies either underway or planned across YUTREPIA and L606 over the next 12 months, the pace and cost of this expanded research program represents a meaningful step-up in spending that investors will likely watch closely relative to the company's ability to continue growing profitability alongside pipeline investment.

Litigation and Sales Force Expansion Remain Key Variables

Management said it continues to await a ruling in ongoing Patent litigation with a competitor, noting no change in its confidence in the probability of success based on arguments made at trial, though the timing of a decision remains outside the company's control. The company's recently expanded sales force, which began fieldwork in June, is expected to deepen existing prescriber relationships while extending reach into community-based physicians, an area management believes remains significantly under-penetrated relative to the broader patient population eligible for therapy.

Conclusion

Liquidia's record quarter and reiterated confidence in surpassing $1 billion in net revenue in 2027 reflect sustained momentum in YUTREPIA adoption across both prescriber and payer channels, even as the company steps up research spending to support a broadening pipeline. The outcome of ongoing patent litigation and the pace at which the expanded sales force converts community-based referrals into new patient starts represent the most significant variables that could influence the trajectory of growth from here.